Compare KSCP & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSCP | ACRV |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 52.4M |
| IPO Year | 2022 | 2022 |
| Metric | KSCP | ACRV |
|---|---|---|
| Price | $3.44 | $1.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $17.00 | $11.67 |
| AVG Volume (30 Days) | ★ 867.9K | 553.5K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.54 | 15.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,335,000.00 | N/A |
| Revenue This Year | $218.66 | N/A |
| Revenue Next Year | $54.32 | $568.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.91 | N/A |
| 52 Week Low | $2.92 | $1.05 |
| 52 Week High | $10.13 | $3.56 |
| Indicator | KSCP | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 67.02 |
| Support Level | $3.09 | $1.73 |
| Resistance Level | $4.50 | $2.47 |
| Average True Range (ATR) | 0.34 | 0.11 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 17.24 | 86.61 |
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.